Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Thomas Gniadek

Internal Medicine Waterbury, CT Medical Doctor

NPI 1972591931 CMS profile 179983

1389 W Main St, Suite 224, Waterbury, CT 06708

Open in the dashboard

General payments

$3,046

172 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Thomas Gniadek of Waterbury, CT is reported in the CMS Open Payments database as having received $3,046 across 172 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,295 78
2024 General $799 42
2023 General $394 16
2022 General $93 5
2021 General $30 1
2020 General $55 3
2019 General $382 27

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thomas Gniadek
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Thomas Gniadek were reported at $1,295. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Thomas Gniadek Internal Medicine median Middle half National median
2019 $382 $159 $48–$570 $163
2020 $55 $119 $33–$402 $114
2021 $30 $135 $37–$521 $132
2022 $93 $141 $42–$496 $149
2023 $394 $149 $45–$519 $160
2024 $799 $154 $47–$537 $164
2025 $1,295 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $663 33 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $539 30 payments
  3. Lilly USA, LLC $242 10 payments
  4. Insulet Corporation $237 17 payments
  5. Novo Nordisk Inc $236 20 payments
  6. Xeris Pharmaceuticals, Inc. $209 13 payments
  7. Amgen Inc. $160 7 payments
  8. Merck Sharp & Dohme Corporation $121 12 payments
  9. Medtronic, Inc. $110 3 payments
  10. Novartis Pharmaceuticals Corporation $101 5 payments
  11. Other $428 22 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,035 171 payments
  2. Education $12 1 payment
Products named General payments · program years 2019–2025
  1. FreeStyle Libre 3 $559 28 payments
  2. JARDIANCE Diabetes $522 29 payments
  3. GVOKE HYPOPEN $190 12 payments
  4. Omnipod $172 14 payments
  5. JARDIANCE Diabetes $160 6 payments
  6. TEPEZZA $122 5 payments
  7. Ozempic $120 12 payments
  8. JANUVIA $116 11 payments
  9. MINIMED 780G $110 3 payments
  10. LEQVIO $101 5 payments
  11. Other $1,410 85 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 140 drugs

Part D claims

8,686

Median for Endocrinology: 1,959

Drug cost

$1,830,051

Median for Endocrinology: $890,201

Branded share of claims

32.5%

Median for Endocrinology: 57%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 394 $523,327
Ozempic Semaglutide Brand 114 $148,131
Jardiance Empagliflozin Brand 104 $142,766
Tresiba Flextouch U-100 Insulin Degludec Brand 136 $87,833
Farxiga Dapagliflozin Propanediol Brand 57 $81,726
Creon Lipase/Protease/Amylase Brand 21 $75,695
Januvia Sitagliptin Phosphate Brand 49 $70,083
Eliquis Apixaban Brand 80 $63,131
Humulin R U-500 Kwikpen Insulin Regular, Human Brand 23 $50,182
Toujeo Solostar Insulin Glargine,hum.Rec.Anlog Brand 34 $49,984

The 10 drugs with the highest cost, of 140 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 6,527 Part D prescribers listed as Endocrinology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 21 billing codes

Paid by Medicare

$77,003

Of which drugs: $5,680

Medicare patients

326

Average age 77

Services billed

13,096

206 women, 120 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 52%
Diabetes 44%
Ischemic heart disease 34%
Atrial fibrillation 25%
Heart failure 19%
Chronic kidney disease 19%
Osteoporosis 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 20 20 $1,636

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $305
  • Lilly USA, LLC $25
$330 104 —
GVOKE HYPOPEN
  • Xeris Pharmaceuticals, Inc. $145
$145 22 —
TEPEZZA
  • Amgen Inc. $46
$46 — —
XYOSTED
  • Antares Pharma, Inc. $16
$16 — —
Ozempic
  • Novo Nordisk Inc $14
$14 114 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

172 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Connecticut

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record